Overview

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A phase II Study of CS0159 in Chinese patients with PSC(Primary Sclerosing Cholangitis)
Phase:
Phase 2
Details
Lead Sponsor:
Cascade Pharmaceuticals, Inc